AAAAAA

   
Results: 1-7 |
Results: 7
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer - A phase III randomized multicenter study
Authors: Ron, IG Wigler, N Borovik, R Brufman, G Rizel, S Shani, A Brenner, J Farbstein, H Dale, A Inbar, MJ Brenner, HJ Chaitchik, S Catane, R
Citation: Ig. Ron et al., CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer - A phase III randomized multicenter study, AM J CL ONC, 24(4), 2001, pp. 323-327
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk inBRCA2 but not BRCA1 carriers
Authors: Levy-Lahad, E Lahad, A Eisenberg, S Dagan, E Paperna, T Kasinetz, L Catane, R Kaufman, B Beller, U Renbaum, P Gershoni-Baruch, R
Citation: E. Levy-lahad et al., A single nucleotide polymorphism in the RAD51 gene modifies cancer risk inBRCA2 but not BRCA1 carriers, P NAS US, 98(6), 2001, pp. 3232-3236
Cancer patient expectations of and communication with oncologists and oncology nurses: the experience of an integrated oncology and palliative care service
Authors: Sapir, R Catane, R Kaufman, B Isacson, R Segal, A Wein, S Cherny, NI
Citation: R. Sapir et al., Cancer patient expectations of and communication with oncologists and oncology nurses: the experience of an integrated oncology and palliative care service, SUPP CARE C, 8(6), 2000, pp. 458-463
BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials
Authors: Levy-Lahad, E Krieger, M Gottfeld, O Renbaum, P Klein, G Eisenberg, S Lahad, A Kaufman, B Catane, R
Citation: E. Levy-lahad et al., BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials, J CELL BIOC, 2000, pp. 13-18
An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer
Authors: Chertin, B Spitz, IM Lindenberg, T Algur, N Zer, T Kuzma, P Young, AJM Catane, R Farkas, A
Citation: B. Chertin et al., An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer, J UROL, 163(3), 2000, pp. 838-844
Synergistic anti-tumoral effect of paclitaxel (taxol)+AS101 in a murine model of B16 melanoma: Association with Ras-dependent signal-transduction pathways
Authors: Kalechman, Y Longo, DL Catane, R Shani, A Albeck, M Sredni, B
Citation: Y. Kalechman et al., Synergistic anti-tumoral effect of paclitaxel (taxol)+AS101 in a murine model of B16 melanoma: Association with Ras-dependent signal-transduction pathways, INT J CANC, 86(2), 2000, pp. 281-288
Cancer pain: Knowledge and attitudes of physicians in Israel
Authors: Sapir, R Catane, R Strauss-Liviatan, N Cherny, NI
Citation: R. Sapir et al., Cancer pain: Knowledge and attitudes of physicians in Israel, J PAIN SYMP, 17(4), 1999, pp. 266-276
Risultati: 1-7 |